BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment
about
Interstitial lung disease: progress and problemsDiagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyTuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Effect of response format for clinical vignettes on reporting quality of physician practice.Can ELISpot replace the tuberculin skin test for latent tuberculosis?Fatal Unusual Miliary Tuberculosis in which a Patient Developed Acute Respiratory Distress Syndrome Induced by Infliximab: An Autopsy Case Report.Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapyDiagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Clinical use of anti-TNF therapy and increased risk of infectionsRheumatoid arthritis-associated interstitial lung disease: diagnostic dilemmaQuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy.Diagnosis and treatment of latent tuberculosis infection.A new diagnosis of acute myeloid leukaemia complicated by peripancreatic tuberculous lymphadenitisInhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonistsSerious infections with antirheumatic therapy: are biologicals worse?Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trialAPLAR rheumatoid arthritis treatment recommendations.Crohn's disease or TB--the perennial question and diagnostic pitfalls.Psoriatic disease and tuberculosis nowadays.Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research.Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the ClinicianIncidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline--a longitudinal analysis after using TNFa blockersTuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort studyInfliximab for the treatment of psoriasis.Screening for tuberculosis infection prior to initiation of anti-TNF therapy.Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.IFN-gamma release assays in tuberculosis management in selected high-risk populations.Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists.CNS Demyelination with TNF-α BlockersSingle-centre experience of granulomatous interstitial nephritis-time for a new approach?Tuberculosis and anti-TNF treatment: experience of a central London hospital.Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The risk of tuberculosis in patients treated with TNF antagonists.New insights into gastrointestinal and hepatic granulomatous disorders.
P2860
Q24655716-FC2D3E14-746F-440D-83ED-63251C8F3172Q27005716-43DCE2B4-C04F-4B41-9309-B50F603557C8Q30799235-0E237990-75AA-4406-9E2E-8F5B3A465FEEQ33488112-97AB24F6-B094-48F4-B03B-C52799A9ACDAQ33524774-D5469898-B7C6-4691-AC7D-2168CD6E3D85Q33818727-EF3F6C19-E01E-4BBF-8C65-3CC988742F02Q33836681-23DF344E-1DDF-4DAE-98B6-AC03DB249342Q33882852-6D9683A2-31C2-4D80-AA86-5DDC382450DEQ34081925-3A4F36CD-6CE8-4057-985E-9BA693C1AD12Q34338096-A0DF9EF5-EF36-4FDF-9781-A4E929AF22C1Q35029858-7C945A05-2D9E-4E9E-BF3F-FFA90BC58C83Q35154706-9EAE68D1-6FF9-46DE-B079-E7681478CFB6Q35199257-7B8A09DB-5759-4D11-9D83-AF4CF90D0422Q35307280-6F4473B4-66B7-4058-9BBB-3311FCA12435Q35572620-F45E3C2F-038A-4664-A713-DA6128146860Q35605635-3CFA169B-B1C8-421D-9EB8-D9E41BAD61F2Q35638259-CE14F39E-2E8D-42E8-8910-3CD38FE7BB7FQ35671005-9F65E5AB-6581-49DB-BA89-CCF168F39BA4Q35762912-8B6B182F-DEEF-4A9B-B724-6B7ACE284B2CQ35919411-ABB26A4C-3558-4593-9B2C-CAAD72379A81Q35974892-1135096C-922C-4C3E-BD7A-708D8B0FE5F0Q35996265-E27EE22B-749B-4387-BB03-21D25A0DDF30Q36059338-F46C9CBC-D3D5-46AD-9DCA-B0083DF75EEAQ36321468-D4741547-D7E1-4289-9388-0D1E74069076Q36346686-E69404C8-0C3A-42C1-A531-900E62E0CD37Q36541961-3B73CEB3-3FA7-4F3A-A033-D0CFF90B6865Q36995803-0E22D1D0-7C72-407D-844A-5D92EF2DD68FQ37033874-D453E479-1F11-451B-B00B-2D19B46D4F7DQ37221167-D35B5D62-4243-4F41-A861-2AB9553C7FBDQ37290665-C35ED44A-364C-4AE6-830D-D03E6B2EC77BQ37418061-7CA4FF68-8364-4E44-82FB-EF1A1A39F800Q37467519-1D32BAF2-A002-4E44-8FB4-197FA3D143D1Q37714705-B837174E-1F5A-42E4-B54A-ED20A3668738Q37719132-357D33F5-29A3-4A88-B159-9264FDF343EFQ37738191-86C937C2-B2CF-4B8D-A529-BC68697443DAQ37802766-C8027B08-DA92-42E4-97C3-56AC4E6677F2Q37810305-9220B96C-6A71-4069-80D2-65D2EC675C38Q37814549-D4FC84D3-96C6-4534-933C-B776E1363812Q37877262-85BEFD08-F01E-49D3-AA32-A79F0A9A781DQ37911957-F08CF0BC-1220-440C-83DA-B3B635B4E4B2
P2860
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@ast
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@en
type
label
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@ast
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@en
prefLabel
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@ast
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@en
P2860
P921
P356
P1433
P1476
BTS recommendations for assess ...... start anti-TNF-alpha treatment
@en
P2093
British Thoracic Society Standards of Care Committee
P2860
P304
P356
10.1136/THX.2005.046797
P407
P577
2005-07-29T00:00:00Z